We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMCLIN
RNS Number : 0247E
Clinigen Group plc
06 February 2018
6 February 2018
Notification of half year results date
Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its half year results for the six months ended 31 December 2017 on Tuesday, 27 February 2018.
A group analyst briefing will be held at 9:30am on Tuesday, 27 February 2018 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register.
-Ends-
Contact Details
Hot Features
Premium
Clinigen Group plc Tel: +44 (0) 1283
495 010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief Financial
Officer
Matt Parrish, Head of Investor
Relations
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard (Corporate
Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners (media Tel: +44 (0) 20
relations) 7457 2020
Melanie Toyne-Sewell / Alex
Shaw Email: clinigen@instinctif.com
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORKQLBBVLFLBBF
(END) Dow Jones Newswires
February 06, 2018 04:22 ET (09:22 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
